Abstract

Cannabis and cannabinoids are often considered in the treatment of Parkinson’s Disease (PD). The purpose of this paper was to perform a systematic review of the available data on cannabis treatment. We aimed to assess randomised trials as well as surveys among patients. We identified 569 papers on PD and cannabinoid treatment. Of these, there were only seven papers featuring randomised trials on the effects of different cannabinoids on PD. The results of these trials did not support the efficacy of cannabinoids in the treatment of motor signs of PD. Based on the available data, we conclude that there is currently insufficient data to support the administration of cannabinoids to PD patients. Larger, randomised studies of cannabis use in PD should be conducted.

Details

Title
Cannabis in Parkinson’s Disease — the patient’s perspective versus clinical trials: a systematic literature review
Author
Figura, Monika 1   VIAFID ORCID Logo  ; Koziorowski, Dariusz 2   VIAFID ORCID Logo  ; Sławek, Jarosław 3   VIAFID ORCID Logo 

1  Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Poland. [email protected] 
2  Department of Neurology, Faculty of Health Science, Medical University of Warsaw, Poland 
3  Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Poland 
First page
21
End page
27
Publication year
2022
Publication date
2022
Publisher
Wydawnictwo Via Medica
ISSN
00283843
e-ISSN
18974260
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.5603/PJNNS.a2022.0004
ProQuest document ID
2692719376
Copyright
© 2022. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.